Elizabeth Ballantyne

Empowering residents and improving governance in low income communities through urban greening

C. Pearson, Nola-Kate Seymoar, Elizabeth Ballantyne, 2010 .

Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial

J. Smith, A. Morice, L. Mcgarvey, 2019, Clinical Problems.

Edinburgh Research Explorer Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized controlled trial

Richard A. Anderson, M. Kerr, H. Joffe, 2020 .

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial

M. Kerr, H. Joffe, Elizabeth Ballantyne, 2020, Menopause.

Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women

W. Dhillo, M. Kerr, K. Donaldson, 2021, The Journal of clinical endocrinology and metabolism.

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

J. Bolognese, N. Panay, J. Simon, 2023, Menopause.